Loading...
•
Jun 30, 2020
Teva Q2 2020 Earnings Report
Reported revenues of $3.9 billion, GAAP diluted EPS of $0.13, non-GAAP diluted EPS of $0.55, and free cash flow of $582 million
Key Takeaways
Teva Pharmaceutical Industries Ltd. reported a decrease in revenues of 7% to $3.9 billion compared to the second quarter of 2019, mainly due to lower revenues from generics, OTC, and COPAXONE in all regions. GAAP diluted EPS was $0.13 and non-GAAP diluted EPS was $0.55. Free cash flow was $582 million. The company reaffirmed its full year 2020 business outlook.
Experienced lower sales of generic and OTC products in all regions.
Profitability and free cash flow were strong, allowing for net debt reduction.
Progress made with growth drivers, including AJOVY auto-injector launch in the U.S. and AUSTEDO approval in China.
Remains committed to serving society and stakeholders with critical and accessible medicines.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Full year 2020 business outlook reaffirmed: Net revenues of $16.6 - $17 billion EBITDA of $4.5 - $4.9 billion EPS of $2.30 - $2.55 Free cash flow of $1.8 - $2.2 billion
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...